Oncology · ChemotherapyRegulatory Approvalregulatorymid-term

Actavis Inc. Submits Supplement for Gemcitabine Hydrochloride (ANDA204549)

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/25/2026, 12:31:17 PM

Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of a supplemental application for Gemcitabine Hydrochloride by Actavis Inc. is significant as it may alter the competitive landscape for generic chemotherapy agents. Portfolio and strategy teams should closely monitor the FDA's review process to anticipate market dynamics and pricing strategies. Regulatory context from FDA (FDA AP — GEMCITABINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio and strategy teams should assess the potential market entry of this generic product and its implications for pricing and market share. The strongest clinical anchor is A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Chemotherapy, 8 regulatory and 4 competitive items passed relevance filtering for Gemcitabine Hydrochloride.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves Supplemental Application for OGSIVEO (Nirogacestat Hydro bromide) (Humanexa Signals) — moderate corpus alignment. Secondary pressure from Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer. This submission may impact the competitive landscape for generic chemotherapy agents, particularly for those targeting similar indications as Gemcitabine.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GEMCITABINE HYDROCHLORIDE (SUPPL) (FDA). Entity match (gemcitabine hydrochloride); Regulatory pathway relevance (nda). The standard review status indicates a typical timeline for approval, but any delays or changes could influence market readiness and compliance strategies.

Key Risks

Elevated medium regulatory exposure for Gemcitabine Hydrochloride could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The potential entry of this generic product could affect pricing and market share for existing chemotherapy agents, impacting revenue streams for competitors.
Upside for Gemcitabine Hydrochloride may improve if A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio and strategy teams should assess the potential market entry of this generic product and its implications for pricing and market share.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any updates on approval status for ANDA204549.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GEMCITABINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (gemcitabine hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CIPROFLOXACIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CIPROFLOXACIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Approves Supplemental Application for OGSIVEO (Nirogacestat Hydro bromide)
Humanexa Signalsmedium relevance
Moderate corpus alignment
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for LEQEMBI Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Acute kidney injury after cytoreductive surgery and HIPEC: incidence and timing in a 10-year single-center cohort.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-depende
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Decoding osteosarcoma pathogenesis: the pivotal influence of m(6)A modification.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Gemcitabine Hydrochloride

Commercial impact

medium

The potential entry of this generic product could affect pricing and market share for existing chemotherapy agents, impacting revenue streams for competitors.

Regulatory impact

medium

The standard review status indicates a typical timeline for approval, but any delays or changes could influence market readiness and compliance strategies.

What to watch

Monitor the FDA's review timeline and any updates on approval status for ANDA204549.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.